Archival ReportThe Hallucinogen DOI Reduces Low-Frequency Oscillations in Rat Prefrontal Cortex: Reversal by Antipsychotic Drugs
Section snippets
Animals
Male albino Wistar rats (250–320 g, Iffa Credo, Lyon, France) were kept in a controlled environment (12-hour light-dark cycle, 22 ± 2°C) with food and water provided ad libitum. Animal care followed the European Union regulations (O.J. of E.C. L358/1 18/12/1986).
Drugs and Reagents
Clozapine and DOI were obtained from Sigma/RBI (Natick, Massachusetts); M100907 [R-(+)-alpha-(2,3-dimethoxyphenil)-1-[4-fluorophenylethyl]-4-piperidinemethanol] (Lilly code LY 368675) was from Eli Lilly (Indianapolis, Indiana), and
Effects of DOI on Pyramidal Neuron Activity in mPFC
The effects of intravenous (IV) administration of DOI on the discharge rate of pyramidal neurons in the rat mPFC have been previously described (23). Here we extend our analysis of these data by showing the effect of DOI on burst firing and LFP. In the subgroup of units in which firing rate was increased by DOI (.05–0.3 mg/kg IV; n = 18), a parallel increase in the number of spikes fired in bursts, the total number of bursts and the duration of burst episodes was observed (Table 1). Conversely,
Discussion
This study sheds new light on the neurobiological basis of the psychotomimetic effect of the 5-HT2A/2C receptor agonist DOI. Previous in vitro studies showed that DOI increased spontaneous and evoked EPSCs in layer V pyramidal neurons of the rat mPFC (24, 25). Subsequent in vivo studies indicated that systemic DOI administration markedly altered the firing rate of pyramidal neurons with an overall increase in discharge (23). Likewise, DOI increased high-frequency network activity in rat mPFC
References (75)
- et al.
The reduced neuropil hypothesis: a circuit based model of schizophrenia
Biol Psychiatry
(1999) - et al.
Catching up on schizophrenia: Natural history and neurobiology
Neuron
(2000) - et al.
Prefrontal neurons and the genetics of schizophrenia
Biol Psychiatry
(2001) - et al.
Decreased density of tyrosine hydroxylase-immunoreactive axons in the entorhinal cortex of schizophrenic subjects
Biol Psychiatry
(2000) - et al.
Neurobiology of schizophrenia
Curr Opin Neurobiol
(1997) How antipsychotics become anti-“psychotic”—from dopamine to salience to psychosis
Trends Pharmacol Sci
(2004)- et al.
Ketamine-induced NMDA receptor hypofunction as model of memory impairment and psychosis
Neuropsychopharmacology
(1999) Hallucinogens
Pharmacol Ther
(2004)- et al.
Blockade of the discriminative stimulus effects of DOI by MDL 100907 and the “atypical” antipsychotics, clozapine and risperidone
Eur J Pharmacol
(1994) - et al.
Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells
Neuropharmacology
(1997)
Serotonin, via 5-HT2A receptors, increases EPSCs in layer v pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release
Brain Res
5-HT2 and 5-HT1A receptors mediate opposing responses on membrane excitability in rat association cortex
Neuroscience
Determination of antidromic excitation by the collision test: problems of interpretation
Brain Res
Restricted cortical termination fields of the midline and intralaminar thalamic nuclei in the rat
Neuroscience
The intralaminar and midline nuclei of the thalamusAnatomical and functional evidence for participation in processes of arousal and awareness
Brain Res Rev
Prefrontal cortical network activity: opposite effects of psychedelic hallucinogens and and D1/D5 receptor activation
Neuroscience
Grouping of brain rhythms in corticothalamic systems
Neuroscience
The prefrontal cortex and the integration of sensory, limbic and autonomic information
Prog Brain Res
Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior
Neuron
A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in neocortex
Neuroscience
Inhibition of 5-hydroxytryptamine neuronal activity by the 5-HT agonist, DOI
Eur J Pharmacol
5-HT2A receptor stimulation by DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens
Brain Res
Radioreceptor binding profile of the atypical antipsychotic olanzapine
Neuropsychopharmacology
Do novel antipsychotics have similar pharmacological characteristics?A review of the evidence
Neuropsychopharmacology
Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography
Brain Res
Serotonin 5-HT2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats
Neuropharmacology
M100907, a selective 5-HT2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex
Brain Res
Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery
Trends Pharmacol Sci
Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology
Neuron
Slow-wave activity during non-REM sleep in men with schizophrenia and major depressive disorders
Psychiatry Res
Alterations in medial prefrontal cortical activity and plasticity in rats with disruption of cortical development
Biol Psychiatry
The neuropathology of schizophreniaA critical review of the data and their interpretation
Brain
Cortical inhibitory neurons and schizophrenia
Nat Rev Neurosci
The Prefrontal CortexAnatomy, Physiology and Neuropsychology of the Frontal Lobe
An integrative theory of prefrontal cortex function
Annu Rev Neurosci
Cognitive impairment in schizophrenia is the core of the disorder
Crit Rev Neurobiol
Prefrontal dopamine D1 receptors and working memory in schizophrenia
J Neurosci
Cited by (91)
Longitudinal alterations of modular functional-metabolic coupling in first-episode schizophrenia
2022, Journal of Psychiatric ResearchCitation Excerpt :For instance, olanzapine could improve the temporal response within the DMN by modulating the dopaminergic pathway directly in the posterior cingulate cortex, or indirectly in the vmPFC of schizophrenia patients (Hu et al., 2017). Animal studies reported that antipsychotics could reverse cortical synchronization and functional connectivity after disruption with hallucinogenic drugs (Celada et al., 2008; Kargieman et al., 2012). Overall, our results support that antipsychotic treatment altered the functional connections within the DMN module and between the DMN and the other functional modules longitudinally in FES patients.
Reduced frontal slow wave density during sleep in first-episode psychosis
2019, Schizophrenia Research